发布时间:2019-05-22 14:00 原文链接: CreationandUseofInfectiousVirusVector

Creation and use of your infectious vector:


  1. Plate 5 x 105 293T cells in 6 cm2 dishes containing 5 ml of media. (This can be scaled up if desired).

  2. The following day set up (use polypropylene tubes for this; polystyrene tubes DO NOTwork!).

  • 1 ug retroviral DNA encoding gene X

  • 1 ug packaging plasmid (such as pCLEco, pCLampho, pUMVC, pHR’CVM8.2 deltaR etc.). If you are using a 3 plasmid system then:

  • for lenti: 1 μg packaging (pHR’8.2deltaR) at a 8:1 ratio with the envelope plasmid (pCMV-VSV-G).

  • for MuLV: the packaging plasmid (pUMVC3) at a 8:1 ratio with the envelope plasmid (pCVM-VSV-G)-a total of 1ug.

  • DME without serum to 94μl

  • 6 μl Fugene


    Mix and wait 15 to 30 minutes at room temperature

    Add to 293T cells without touching the sides of the dish (DO NOT CHANGE MEDIA).

    If you are using amphotropic virus then move immediately to BL2+ in a secondary container, which has an absorbent material. (This does not mean a couple of hours; it means Immediately!). The rest of this protocol is the same for all virus---the BL2+ safety practices are in place if you are using amphotropic viruses.


  1. The following day change the media to whatever media you wish to use when infecting target cells. 293T cells are easily detached so remember not to put the media directly onto to cells but rather “run” it down the side of the dish. Remember that you will get the highest titer virus when your cells are “happy.” Plate out your target cells.

  2. The following day. Remove the medium from the 293T cells and use a 0.45 u syringe filter to remove any 293T cells. DO NOT use the 0.2 u filter, as it is likely to shear the envelope from your virus making it noninfectious.

    Note: After filtering, the filter should be removed and placed in the biohazard bag in the hood and the syringe rinsed with bleach and decontaminated for a minimum of 20 minutes. It is useful to place, in advance, a plastic beaker with bleach in the hood for this.


  1. Add 8 to 10 μg/ml of polybrene (Hexadimethrine bromide) or protamine sulfate to the virus and add to the target cells.


  1. Carry out infection for 1 to 4 hours. Remove virus and replace with fresh media.

    Note: If you wish to do a second infection the following day, it is important to put fresh medium on the cells and not let the virus remain on the cells overnight. The medium contains huge amounts of envelope both associated and unassociated with viral particles that will bind all the cell surface receptors required for virus adsorption, causing their down-regulation. Hence, if you don’t change the medium after the initial infection, very few receptors will be available for the next round of infection. In addition, very few cells tolerate the presence of that much envelope for extended periods of time (i.e. a lot of your cells may die).

  1. Allow the cells to recover and begin to express the virus-encoded genes. The cells usually require 48 hours for this to occur.

  2. Add drug if you are scoring for the presence of a vector that carries the appropriate drug resistance marker. Prior to this step it is advisable each time you do an infection to titrate the drug to be used for selection in order to know precisely how much to add. In addition, it is necessary to bring an extra plate of uninfected cells that are often referred to as “canaries.” Add drug to both plates. When your canaries are dead, you can remove the drug.


Testing for Horizontal Transfer (When using the 3 or 4 plasmid system you are only required to do this every couple of months on a randomly chosen virus prep. When using the two plasmid system or packaging cell lines you must do this EVERY time you make a new virus stock!!)

  1. Once you have cells that emerged from selection and are growing, you can test for horizontal transfer, i.e. for the inadvertent generation of replication-competent virus, which may have occurred during the course of your experiment. Please note that the vector-infected cells, prepared as described above, must be growing and “happy.” You should essentially treat them as if they were 293T cells. When they are 50 to 75% confluent, remove medium from these cells, filter it, add polybrene, and infect your new target cells.

The question is often raised concerning which cells should be used as infectable target cells in order to test for the horizontal transfer resulting from the inadvertent creation of infectious retrovirus. The best choice is a cell type that is easily infectable with the specific viral vector you happen to be using. Useful cells here are those that have a relatively rapid cell cycle and are known to be susceptible to infection by the retroviral vector (and therefore to the envelope glycoprotein) that you are using. At present (6/01), we have found that C3H10T1/2 cells are especially useful here.


  1. Wait 48 hours and add selection drug to these cells AND to a set of canary cells. Both sets of cells should die at the same time. If the canaries die but the cells infected by the viral vector don’t do so with identical kinetics, then you have good evidence that horizontal transfer resulting from the inadvertent generation of an infectious retrovirus has occurred, and all cells and media resulting from this experiment should be destroyed by the addition of bleach and subsequent autoclaving.

  2. Many have asked what to do if they have used green fluorescent protein (GFP) instead of a selectable drug marker in the vector. In this case, you proceed exactly as outlined above. 48 hours later after infection of test target cells, instead of adding drug you lift the cells and the canaries and resuspend them in 2% formaldehyde or paraformaldehyde and run FACS to determine if any of the cells are green. You should run at least 10,000 cells to be sure. If you don’t know how to run flow speak with someone who does. Also, both formaldehyde and paraformaldehyde autofluoresce in the green channel, so it is important that you have a set of infected cells canary here as well.


Selection (drug concentrations to be used with CH310T1/2 cells):

  • Neomycin 1 mg/ml

  • Hygromycin 300 μg/ml

  • Puromycin 2 μg/ml

  • Zeocin 1.2 mg/ml

  • Blastocidin 15 μg/ml


相关文章

回顾和预测现代生物制药为何青睐一次性生物反应器?

一次性反应技术近年来逐渐成为生物制药企业、CDMO公司的选择,由于其污染风险少、清洁、验证成本低的特点,备受业内好评。一次性技术选择不仅仅为生物制药企业和CDMO公司带来一种创新方向的选择,更重要的是......

科学家将人工智能技术成功用于蛋白质复合物结构预测

蛋白质作为构成人体组织器官的支架和主要物质,在人体生命活动中起着重要作用。蛋白质的相互作用能产生许多效应,如形成特异底物作用通道、生成新的结合位点、失活、作用底物专一性和动力学变化等,细胞的代谢、信号......

发力癌症分子病理诊断,无锡臻和全资收购TissueofOrigin®

2021年9月9日,无锡臻和生物科技有限公司(以下简称“臻和科技”)与美国VyantBio公司签署TissueofOrigin®(以下简称“TOO®”)全球权益和专利转让协议,全资收购这款唯一获FDA......

这3个杂志撤回中国学者249篇文章,包含上交、中山等名校

2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同时撤回了中国学者49篇文章。从2019年开始,Journalo......

肿瘤治疗的强心剂,中国学者开发肿瘤治疗新策略

磷酸甘油酸突变酶1(PGAM1)通过其代谢活性以及与其他蛋白质(例如α平滑肌肌动蛋白(ACTA2))的相互作用,在癌症代谢和肿瘤进展中起关键作用。变构调节被认为是发现针对PGAM1的高选择性和有效抑制......

肿瘤治疗的强心剂,中国学者开发肿瘤治疗新策略

磷酸甘油酸突变酶1(PGAM1)通过其代谢活性以及与其他蛋白质(例如α平滑肌肌动蛋白(ACTA2))的相互作用,在癌症代谢和肿瘤进展中起关键作用。变构调节被认为是发现针对PGAM1的高选择性和有效抑制......

llumina宣布推出新型基因分型芯片|支持AllofUs研究计划

2018年12月6日,来自圣迭戈的消息——Illumina公司(纳斯达克股票代码:ILMN)今天宣布推出新型高密度基因分型芯片Infinium™GlobalDiversityArray。这款芯片设计源......

SDSPAGE异常电泳现象及分析SDSPAGEHallofShame

SDS-PAGE异常电泳现象及分析SDS-PAGEHallofShame.pdf  很不错的东东~~推荐下~......

Preparationofdenaturing6%

Preparationofdenaturing6%polyacrylamidegelsformicrosatelliteanalysis(alsoforSSAP,high-resolutionIRAP......